Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial

OBJECTIVE: Irinotecan-based doublet chemotherapy strategy was standard second-line backbone for patients with oxaliplatin-refractory metastatic colorectal cancer. The aim of this study was to evaluate tolerability and efficacy of raltitrexed combined with irinotecan biweekly administered as the seco...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ke, Zhou, Yu-Wen, Chen, Ye, Li, Zhi-Ping, Qiu, Meng, Liu, Ji-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961360/
https://www.ncbi.nlm.nih.gov/pubmed/35343258
http://dx.doi.org/10.1177/10732748221080332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961360/
https://www.ncbi.nlm.nih.gov/pubmed/35343258
http://dx.doi.org/10.1177/10732748221080332

Ejemplares similares